Schroder Investment Management Group
ADCT icon

Schroder Investment Management Group’s ADC Therapeutics ADCT Stock Holding History

Schroder Investment Management Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$431K Hold
418,782
– – ﹤0.01% 1101
2026
Q1 		$1.52M Hold
418,782
– – ﹤0.01% 976
2025
Q4 		$1.47M Buy
+418,782
New +$1.7M ﹤0.01% 939

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Schroder Investment Management Group's ADCT Position: Q2 2026 in Review

Schroder Investment Management Group held its ADC Therapeutics (ADCT) position steady in Q2 2026 at 418,782 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #1101.

Schroder Investment Management Group first reported a position in ADCT in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.52M in Q1 2026. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Schroder Investment Management Group held 418,782 shares of ADC Therapeutics worth $431K as of Q2 2026.
  • Schroder Investment Management Group left its ADC Therapeutics share count unchanged in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #1101 holding.
  • Schroder Investment Management Group first reported a position in ADC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Schroder Investment Management Group's ADC Therapeutics position peaked at $1.52M in Q1 2026.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.